A Review on Inosine Pranobex Immunotherapy for Cervical HPV-Positive Patients
1Department of Gynecology, Military Medical Academy, Sofia, Bulgaria.
Infection and Drug Resistance
|June 9, 2021
Summary
Inosine pranobex (IP) immunotherapy shows significant efficacy in clearing human papillomavirus (HPV) infections and preventing cervical cancer progression. This review highlights IP
Area of Science:
- Immunology
- Oncology
- Virology
Background:
- Persistent cervical human papillomavirus (HPV) infection is a primary risk factor for cervical cancer.
- Host immune status critically influences HPV infection clearance and disease progression.
- While immune system interactions with HPV are partially understood, complete mechanisms remain elusive.
Purpose of the Study:
- To review and synthesize data on inosine pranobex (IP) immunotherapy for cervical HPV-positive patients.
- To evaluate IP's efficacy in managing HPV infections and associated cervical changes.
- To assess IP's role in preventing cervical cancer development.
Main Methods:
- Comprehensive literature search across major databases (Google Scholar, PubMed/MEDLINE, Scopus, Cochrane Library, Research Gate) from 1971-2021.
- Inclusion of prospective controlled trials, observational studies, retrospective studies, meta-analyses, and reviews.
- Focus on studies investigating immunotherapy for cervical HPV infections.
Main Results:
- Prior studies demonstrate strong clinical efficacy for both combined and standalone IP therapy.
- IP treatment effectively reverses HPV-induced cervical changes and prevents disease progression.
- IP enhances host antiviral responses, delays cervical oncogenesis, and promotes rapid HPV clearance.
Conclusions:
- Inosine pranobex (IP) is a viable immunotherapy option for cervical HPV infections.
- IP treatment offers significant benefits in managing HPV-related cervical conditions and preventing cancer.
- Further research may elucidate optimal IP application strategies for cervical HPV management.
Related Concept Videos
02:56Treatment Resistant Cancers
3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
02:49Cancer Therapies
8.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.9K